Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway

Journal of Cellular Physiology

Volumn 216, Issue 2, 2008, Pages 536-542

  Chamoux, Estelle ^a   Houde, Nicolas ^a   L'Eriger, Karine ^a   Roux, Sophie ^a,b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CELL ACTIVATION; CELL CULTURE; CELL DIFFERENTIATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INHIBITION KINETICS; MONOCYTE; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; APOPTOSIS; CASPASE 8; CELLS, CULTURED; CULTURE MEDIA; ENZYME ACTIVATION; HELA CELLS; HUMANS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 46049108371     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21430     Document Type: Article

References (38)

1. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-342.
2. Cassatella MA. 2006. On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils. J Leukoc Biol 79:1140-1149.
3. Colucci S, Brunetti G, Rizzi R, Zonno A, Mori G, Colaianni G, Del Prete D, Faccio R, Liso A, Capalbo S, Liso V, Zallone A, Grano M. 2004. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: The role of the OPG/TRAIL interaction. Blood 104:3722-3730.
4. Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Pignataro P, Tamma R, Grassi FR, Zallone A, Grano M. 2007. The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis 12:1623-1632.
5. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. 2002. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168:1356-1361.
6. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363-14367.
7. Gingery A, Bradley E, Shaw A, Oursler MJ. 2003. Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem 89:165-179.
8. Golden LH, Insogna KL. 2004. The expanding role of PI3-kinase in bone. Bone 34:3-12.
9. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. 1998. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161:2833-2840.
10. Harper N, Farrow SN, Kaptein A, Cohen GM, MacFarlane M. 2001. Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases. J Biol Chem 276:34743-34752.
11. Harper N, Hughes MA, Farrow SN, Cohen GM, MacFarlane M. 2003. Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling. J Biol Chem 278:44338-44347.
12. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. 2000. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12.
13. Holen I, Shipman CM. 2006. Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond) 110:279-291.
14. Holen I, Croucher PI, Hamdy FC, Eaton CL. 2002. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62:1619-1623.
15. Igarashi K, Hirotani H, Woo JT, Stern PH. 2004. Cyclosporine A and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures. Bone 35:47-56.
16. Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishihara T, Takahashi N, Suda T. 1999. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 163:434-442.
17. Kong YY, Boyle WJ, Penninger JM. 2000. Osteoprotegerin ligand: A regulator of immune responses and bone physiology. Immunol Today 21:495-502.
18. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
19. Lincz LF, Yeh TX, Spencer A. 2001. TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 15:1650-1657.
20. Nam SY, Jung GA, Hur GC, Chung HY, Kim WH, Seol DW, Lee BL. 2003. Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci 94:1066-1073.
21. Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE, Holen I. 2004. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 86:269-279.
22. Rivera-Walsh I, Cvijic ME, Xiao G, Sun SC. 2000. The NF-kappa B signaling pathway is not required for Fas ligand gene induction but mediates protection from activation-induced cell death. J Biol Chem 275:25222-25230.
23. Roux S, Chamoux E. 2007. Osteoclast apoptosis. In: Cell apoptotic signalling pathways. Hauppauge, NY: Nova Science Publishers. pp 163-184.
24. Roux S, Lambert-Comeau P, Saint-Pierre C, Lepine M, Sawan B, Parent JL. 2005. Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Biochem Biophys Res Commun 333:42-50.
25. Sandra F, Hendarmin L, Nakamura S. 2006. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): Suppression of TRAIL-induced apoptosis in ameloblastomas. Oral Oncol 42:415-420.
26. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821.
27. Shinohara M, Takayanagi H. 2007. Novel osteoclast signaling mechanisms. Curr Osteoporos Rep 5:67-72.
28. Shipman CM, Croucher PI. 2003. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63:912-916.
29. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ, et al. 1997. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
30. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K. 2001. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 193:661-670.
31. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K. 2001. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7:94-100.
32. Theoleyre S, Wittrant Y, Couillaud S, Vusio P, Berreur M, Dunstan C, Blanchard F, Redini F, Heymann D. 2004. Cellular activity and signaling induced by osteoprotegerin in osteoclasts: Involvement of receptor activator of nuclear factor kappaB ligand and MAPK. Biochim Biophys Acta 1644:1-7.
33. Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, McLaughlin MM, Srinivasula SM, Livi GP, Marshall LA, Alnemri ES, Williams WV, Doyle ML. 2000. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 275:23319-23325.
34. Vitovski S, Phillips JS, Sayers J, Croucher PI. 2007. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: Evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 282:31601-31609.
35. Wang Q, Ji Y, Wang X, Evers BM. 2000. Isolation and molecular characterization of the 5′-upstream region of the human TRAIL gene. Biochem Biophys Res Commun 276:466-471.
36. Wittrant Y, Couillaud S, Theoleyre S, Dunstan C, Heymann D, Redini F. 2002. Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochem Biophys Res Commun 293:38-44.
37. Zauli G, Rimondi E, Nicolin V, Melloni E, Celeghini C, Secchiero P. 2004. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 104:2044-2050.
38. Zauli G, Rimondi E, Stea S, Baruffaldi F, Stebel M, Zerbinati C, Corallini F, Secchiero P. 2008. TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors. J Cell Physiol 214:117-125.